ClinicalTrials.gg
CompletedNCT00358852PRE-COGUpdated Mar 19, 2014

Scale Validation Study for Prediction of Relapse and Short Term Rehospitalization in Patients With Schizophrenia

An observational study in Schizophrenia, sponsored by Janssen-Cilag, S.A.. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-03-19.

Sponsored by Janssen-Cilag, S.A. (part of Johnson & Johnson) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
2,339
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 206 studies in Schizophrenia by Johnson & Johnson — 2 open to participants now, 2 under way, 1 of them phase 3. Schizophrenia · Johnson & Johnson.

Enrollment
5th of 30
2,339 · median 541
Started
2006
with 15 others
Observational
30 of 206
none open now
Registered
54th of 206
by date

Among the 206 studies in Schizophrenia by Johnson & Johnson, this one is the 5th largest by enrollment of the 30 observational ones that give a count, is one of 16 that started in 2006, is one of 30 observational ones, and was the 54th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

2 of the 206 studies in Schizophrenia by Johnson & Johnson are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Schizophrenia by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is to establish and validate a scale/model that can be used to evaluate the duration of time and factors between short term hospital treatment and subsequent relapse periods in patients with schizoaffective/schizophreniform disorders.

Read the detailed description

This is an epidemiological (study of the distribution and determinants of health-related states or events in defined population), multicenter (study conducted at multiple sites), observational (study in which patients are observed), cross-sectional (observation of all patients at one specific point in time), prospective (in which the patients are first identified and then followed forward as time passes) study. The sources of information in the study are units medical short stay psychiatric hospitalization or the acute care of the whole country, and clinical data of the patient at discharge. No intervention will be provided in this study. The general data (age range, gender, highest level of educational attainment, level of family support, substance abuse, events stressors, type of schizophrenia according to DSM-IV criteria [Diagnostic and Statistical Manual fourth], etc) of approximately 2000 schizophrenia and schizoaffective disorder / schizophreniform patients will be collected in this study. No special tests will be done during the study. The study will collect patients' data in electronic data collection workbook and model validation will be used at 6 and 12 months to confirm no relapse / hospitalization. The study observation period corresponds to the 3 years preceding the current relapse and current income (current hospitalization period) and 12 months after admission.

03

Conditions studied

  • Schizophrenia

Keywords

  • Schizophrenia
  • Mental disorder
  • Schizoaffective disorder
  • Schizophreniform disorder
  • Epidemiological study
  • Scale validation
  • Relapse
  • Short Term Hospitalization
  • PRE-COG
  • RISSCH4075
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with schizophrenia, schizoaffective / schizophreniform more than 2 years of evolution and who are admitted to inpatient psychiatric units for short stay acute care setting.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with Schizophrenia or Schizoaffective disorder of more than 2 years evolution and who find themselves admitted in a Short-Term Psychiatric Hospitalization Unit or Acute Unit

Exclusion criteria

Exclusion Criteria:

  • Other patients with a psychiatric pathology different to schizophrenia, schizoaffective/schizophreniform disorders
  • Patients with schizophrenia or schizoaffective/schizophreniform disorders of 2 years, or less evolution
  • Pregnant, lactating, or planning to become pregnant within the next 12 months
05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
2,339 participants (actual)
Patient registry
No

Groups and cohorts

  • Patients with Schizophrenia

    Other: No intervention

Interventions

  • OtherNo intervention

    This is an observational study. The data will be collected of patients suffering from schizophrenia and schizoaffective disorder / schizophreniform.

06

What researchers measure

Primary outcomes

  1. Time to short-term relapse

    Time to early relapse of patients discharged from a short-stay psychiatric hospitalisation unit.

    Time frame: Up to 12 months

  2. Number of readmission of patients

    Readmission in short-stay psychiatric hospital units when the schizophrenia or schizoaffective or schizophreniform disorder relapse.

    Time frame: Up to 12 months

  3. Clinical Global Impression - Severity (CGI-S) Score

    The CGI-S rating scale is used to rate the severity of a patient's psychotic condition on a 7-point scale. It is rated as follows: 1=Normal, not at all ill, 2=Borderline mentally ill, 3=Mildly ill, 4=Moderately ill, 5=Markedly ill, 6=Severely ill, and 7=Among the most extremely ill. Higher scores indicate worsening.

    Time frame: Up to 3 years

Secondary outcomes

  1. Duration of disease

    Time frame: Within 3 years before the study start

  2. Drug abuse

    Time frame: Within 3 years before the study start

  3. Psychiatric diagnosis

    Patients diagnosed with Schizophrenia or Schizoaffective/schizophreniform disorder.

    Time frame: Within 3 years before the study start

  4. Previous stress or event

    Time frame: Within 3 years before the study start

  5. Hospitalizations in the previous 3 years

    Time frame: Within 3 years before the study start

  6. Adherence to the psychiatric treatment

    Time frame: Within 3 years before the study start

  7. Previous pharmacological treatment

    Time frame: Within 3 years before the study start

07

Study locations

No study locations are listed for this record.

08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2006, a primary completion of Sep 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2006
First posted
Aug 1, 2006
Start
Aug 2006
Primary completionActual
Sep 2008
CompletionActual
Sep 2008
Last update
Mar 19, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00358852
Responsible party
Sponsor
First posted
Aug 1, 2006
Start date
Aug 2006
Primary completion
Sep 2008
Completion
Sep 2008
Last update
Mar 19, 2014

Study contacts

Janssen-Cilag S.A., Spain Clinical Trial
study director · Janssen-Cilag, S.A.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion